{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:42:26Z","timestamp":1790199746223,"version":"4.1.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020"},{"name":"Marie Sk\u0142odowska-Curie","award":["860715"],"award-info":[{"award-number":["860715"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Determining the potential cardiotoxicity and pro-arrhythmic effects of drug candidates remains one of the most relevant issues in the drug development pipeline (DDP). New methods enabling to perform more representative preclinical in vitro studies by exploiting induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) are under investigation to increase the translational power of the outcomes. Here we present a pharmacological campaign conducted to evaluate the drug-induced QT alterations and arrhythmic events on uHeart, a 3D miniaturized in vitro model of human myocardium encompassing iPSC-CM and dermal fibroblasts embedded in fibrin. uHeart was mechanically trained resulting in synchronously beating cardiac microtissues in 1 week, characterized by a clear field potential (FP) signal that was recorded by means of an integrated electrical system. A drug screening protocol compliant with the new International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines was established and uHeart was employed for testing the effect of 11 compounds acting on single or multiple cardiac ion channels and well-known to elicit QT prolongation or arrhythmic events in clinics. The alterations of uHeart\u2019s electrophysiological parameters such as the beating period, the FP duration, the FP amplitude, and the detection of arrhythmic events prior and after drug administration at incremental doses were effectively analyzed through a custom-developed algorithm. Results demonstrated the ability of uHeart to successfully anticipate clinical outcome and to predict the QT prolongation with a sensitivity of 83.3%, a specificity of 100% and an accuracy of 91.6%. Cardiotoxic concentrations of drugs were notably detected in the range of the clinical highest blood drug concentration (Cmax), qualifying uHeart as a fit-to-purpose preclinical tool for cardiotoxicity studies.<\/jats:p>","DOI":"10.1093\/toxsci\/kfac108","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T13:49:21Z","timestamp":1665496161000},"page":"47-60","source":"Crossref","is-referenced-by-count":22,"title":["Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform"],"prefix":"10.1093","volume":"191","author":[{"given":"Roberta","family":"Visone","sequence":"first","affiliation":[{"name":"Department of Electronics, Information and Bioengineering, Politecnico di Milano , Milan, 20133, Italy"},{"name":"BiomimX Srl , Milan, 20158, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferran","family":"Lozano-Juan","sequence":"additional","affiliation":[{"name":"Department of Electronics, Information and Bioengineering, Politecnico di Milano , Milan, 20133, Italy"},{"name":"BiomimX Srl , Milan, 20158, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Marzorati","sequence":"additional","affiliation":[{"name":"Accelera Srl , Milan, 20014, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo Walter","family":"Rivolta","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Universit\u00e0 degli Studi di Milano , Milan, 20133, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Pesenti","sequence":"additional","affiliation":[{"name":"Accelera Srl , Milan, 20014, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Redaelli","sequence":"additional","affiliation":[{"name":"Department of Electronics, Information and Bioengineering, Politecnico di Milano , Milan, 20133, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sassi","sequence":"additional","affiliation":[{"name":"Department of Computer Science, Universit\u00e0 degli Studi di Milano , Milan, 20133, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rasponi","sequence":"additional","affiliation":[{"name":"Department of Electronics, Information and Bioengineering, Politecnico di Milano , Milan, 20133, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-2019","authenticated-orcid":false,"given":"Paola","family":"Occhetta","sequence":"additional","affiliation":[{"name":"Department of Electronics, Information and Bioengineering, Politecnico di Milano , Milan, 20133, Italy"},{"name":"BiomimX Srl , Milan, 20158, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"2023013111345500700_kfac108-B1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","article-title":"A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes","volume":"84","author":"Ando","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2023013111345500700_kfac108-B2","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","article-title":"International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment","volume":"24","author":"Blinova","year":"2018","journal-title":"Cell Rep"},{"key":"2023013111345500700_kfac108-B3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/toxsci\/kfw200","article-title":"Comprehensive translational assessment of human- induced pluripotent stem cell derived cardiomyocytes for evaluating drug-induced arrhythmias","volume":"155","author":"Blinova","year":"2017","journal-title":"Toxicol. Sci"},{"key":"2023013111345500700_kfac108-B4","first-page":"717","article-title":"Current strategies of mechanical stimulation for maturation of cardiac microtissues","volume":"13","author":"Carlos-Oliveira","year":"2021"},{"key":"2023013111345500700_kfac108-B5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/toxsci\/kfu084","article-title":"High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays","volume":"140","author":"Clements","year":"2014","journal-title":"Toxicol. Sci"},{"key":"2023013111345500700_kfac108-B6","first-page":"15","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative- Update on progress","volume":"81","author":"Colatsky","year":"2016"},{"key":"2023013111345500700_kfac108-B7","article-title":"Detection and reporting of drug-induced proarrhythmias: Room for improvement","volume":"9(Suppl 4)","author":"Darp\u00f6","year":"2007","journal-title":"Europace"},{"key":"2023013111345500700_kfac108-B8","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/j.bbamcr.2015.10.014","article-title":"Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform","volume":"1863","author":"Denning","year":"2016","journal-title":"Biochim. Biophys. Acta Mol. Cell Res"},{"key":"2023013111345500700_kfac108-B9","first-page":"266","article-title":"Modeling physiological events in 2D vs. 3D cell culture","volume":"32","author":"Duval","year":"2017","journal-title":"Physiology (Bethesda)"},{"key":"2023013111345500700_kfac108-B10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicol. Sci"},{"key":"2023013111345500700_kfac108-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J. Biomol. Screen"},{"key":"2023013111345500700_kfac108-B12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrd1108","article-title":"The impact of drug-induced QT interval prolongation on drug discovery and development","volume":"2","author":"Fermini","year":"2003","journal-title":"Nat. Rev. Drug Discov"},{"key":"2023013111345500700_kfac108-B13","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1542-474X.2003.08413.x","article-title":"The duration of systole in an electrocardiogram in normal humans and in patients with heart disease","volume":"8","author":"Fridericia","year":"2003","journal-title":"Noninvasive Electrocardiol"},{"key":"2023013111345500700_kfac108-B14","first-page":"195","author":"Funck-Brentano","year":"1990"},{"key":"2023013111345500700_kfac108-B15","doi-asserted-by":"crossref","first-page":"112290","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: Useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem"},{"key":"2023013111345500700_kfac108-B16","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.stem.2020.05.004","article-title":"Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease","volume":"26","author":"Giacomelli","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2023013111345500700_kfac108-B17","doi-asserted-by":"crossref","first-page":"104756","DOI":"10.1016\/j.yrtph.2020.104756","article-title":"Repolarization studies using human stem cell-derived cardiomyocytes: Validation studies and best practice recommendations","volume":"117","author":"Gintant","year":"2020","journal-title":"Regul. Toxicol. Pharmacol"},{"key":"2023013111345500700_kfac108-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4287158","article-title":"Young at heart: Pioneering approaches to model nonischaemic cardiomyopathy with induced pluripotent stem cells","volume":"2016","author":"Gowran","year":"2016","journal-title":"Stem Cells International"},{"key":"2023013111345500700_kfac108-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-54849-w","article-title":"Improving the odds of drug development success through human genomics: Modelling study","volume":"9","author":"Hingorani","year":"2019","journal-title":"Sci. Rep"},{"key":"2023013111345500700_kfac108-B20","author":"ICH guideline E14\/S7B","year":"2022"},{"key":"2023013111345500700_kfac108-B21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/clpt.2014.155","article-title":"Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil","volume":"96","author":"Johannesen","year":"2014","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023013111345500700_kfac108-B22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jphs.2018.10.010","article-title":"Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update","volume":"138","author":"Kanda","year":"2018","journal-title":"J. Pharmacol. Sci"},{"key":"2023013111345500700_kfac108-B23","first-page":"174787","article-title":"Role of ranolazine in heart failure: From cellular to clinic perspective","volume":"919","author":"Kaplan","year":"2022"},{"key":"2023013111345500700_kfac108-B24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.stemcr.2018.11.007","article-title":"Development of a human iPSC cardiomyocyte-based scoring system for cardiac hazard identification in early drug safety de-risking","volume":"11","author":"Kopljar","year":"2018","journal-title":"Stem Cell Rep"},{"key":"2023013111345500700_kfac108-B25","doi-asserted-by":"crossref","first-page":"106654","DOI":"10.1016\/j.vascn.2019.106654","article-title":"Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure","volume":"101","author":"Leishman","year":"2020","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2023013111345500700_kfac108-B26","first-page":"85","author":"Lepor","year":"2008"},{"key":"2023013111345500700_kfac108-B27","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/0963689718779346","article-title":"The impact of in vitro cell culture duration on the maturation of human cardiomyocytes derived from induced pluripotent stem cells of myogenic origin","volume":"27","author":"Lewandowski","year":"2018","journal-title":"Cell Transplant"},{"key":"2023013111345500700_kfac108-B28","doi-asserted-by":"crossref","first-page":"38541","DOI":"10.1021\/acsami.2c10669","article-title":"PDMS\u2013PEG block copolymer and pretreatment for arresting drug absorption in microphysiological devices","volume":"14","author":"Mair","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2023013111345500700_kfac108-B29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1039\/C5LC01356A","article-title":"Beating heart on a chip: A novel microfluidic platform to generate functional 3D cardiac microtissues","volume":"16","author":"Marsano","year":"2016","journal-title":"Lab Chip"},{"key":"2023013111345500700_kfac108-B30","first-page":"235","author":"Milani-Nejad","year":"2013"},{"key":"2023013111345500700_kfac108-B31","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/toxsci\/kfy110","article-title":"Cross-site reliability of human induced pluripotent stem cell-derived cardiomyocyte based safety assays using microelectrode arrays: Results from a blinded CiPA pilot study","volume":"164","author":"Millard","year":"2018","journal-title":"Toxicol. Sci"},{"key":"2023013111345500700_kfac108-B32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-1-4939-6661-5_5","article-title":"The CiPA microelectrode array assay with hSC-derived cardiomyocytes: Current protocol, future potential","author":"Millard","year":"2017","journal-title":"Methods Pharmacol. Toxicol"},{"key":"2023013111345500700_kfac108-B33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.112.000570","article-title":"Screening drug-induced arrhythmia events using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays","volume":"128","author":"Navarrete","year":"2013","journal-title":"Circulation"},{"key":"2023013111345500700_kfac108-B34","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3389\/fphys.2017.01073","article-title":"Adult human primary cardiomyocyte-based model for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risk","volume":"8","author":"Nguyen","year":"2017","journal-title":"Front. Physiol"},{"key":"2023013111345500700_kfac108-B35","first-page":"855","author":"Pang","year":"2019"},{"key":"2023013111345500700_kfac108-B36","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3390\/ijms21020657","article-title":"The emergence of human induced pluripotent stem cell-derived cardiomyocytes (HiPSC-CMs) as a platform to model arrhythmogenic diseases","volume":"21","author":"Pourrier","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2023013111345500700_kfac108-B37","author":"Rasponi","year":"2018"},{"key":"2023013111345500700_kfac108-B38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.vascn.2016.08.002","article-title":"Influence of field potential duration on spontaneous beating rate of human induced pluripotent stem cell-derived cardiomyocytes: Implications for data analysis and test system selection","volume":"82","author":"Rast","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"2023013111345500700_kfac108-B39","first-page":"32","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003"},{"key":"2023013111345500700_kfac108-B40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.ahj.2009.02.020","article-title":"Assessing proarrhythmic potential of drugs when optimal studies are infeasible","volume":"157","author":"Rock","year":"2009","journal-title":"Am. Heart J"},{"key":"2023013111345500700_kfac108-B41","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41586-018-0016-3","article-title":"Advanced maturation of human cardiac tissue grown from pluripotent stem cells","volume":"556","author":"Ronaldson-Bouchard","year":"2018","journal-title":"Nature"},{"key":"2023013111345500700_kfac108-B42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/clc.22476","article-title":"Ranolazine in cardiac arrhythmia","volume":"39","author":"Saad","year":"2016","journal-title":"Clin. Cardiol"},{"key":"2023013111345500700_kfac108-B43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J"},{"key":"2023013111345500700_kfac108-B44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023013111345500700_kfac108-B45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/01.RES.10.3.306","article-title":"Electrophysiological study of human heart muscle","volume":"10","author":"Trautwein","year":"1962","journal-title":"Circ. Res"},{"key":"2023013111345500700_kfac108-B46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicol. Sci"},{"key":"2023013111345500700_kfac108-B47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacbts.2020.03.010","article-title":"Limitations of animal studies for predicting toxicity in clinical trials: Part 2: Potential alternatives to the use of animals in preclinical trials","volume":"5","author":"Van Norman","year":"2020","journal-title":"JACC Basic Transl. Sci"},{"key":"2023013111345500700_kfac108-B48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clin. Pharmacol. Ther"},{"key":"2023013111345500700_kfac108-B49","first-page":"046102","article-title":"A microscale biomimetic platform for generation and electro-mechanical stimulation of 3D cardiac microtissues","volume":"2","author":"Visone","year":"2018","journal-title":"."},{"key":"2023013111345500700_kfac108-B50","doi-asserted-by":"crossref","first-page":"035026","DOI":"10.1088\/1758-5090\/abe4c4","article-title":"Micro-electrode channel guide (\u00b5ECG) technology: An online method for continuous electrical recording in a human beating heart-on-chip","volume":"13","author":"Visone","year":"2021","journal-title":"Biofabrication"},{"key":"2023013111345500700_kfac108-B51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10787-011-0099-z","article-title":"Dissolution and pharmacokinetics of a novel micronized aspirin formulation","volume":"20","author":"Voelker","year":"2012","journal-title":"Inflammopharmacology"},{"key":"2023013111345500700_kfac108-B52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167348","article-title":"Electrophysiological characteristics of human iPSC-derived cardiomyocytes for the assessment of drug-induced proarrhythmic potential","volume-title":"PloS one","author":"Yamamoto","year":"2016"},{"key":"2023013111345500700_kfac108-B53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jphs.2018.02.005","article-title":"Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes","volume":"136","author":"Yamazaki","year":"2018","journal-title":"J. Pharmacol. Sci"},{"key":"2023013111345500700_kfac108-B54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/CIRCRESAHA.114.300558","article-title":"Engineering adolescence: Maturation of human pluripotent stem cell-derived cardiomyocytes","volume":"114","author":"Yang","year":"2014","journal-title":"Circ. Res"},{"key":"2023013111345500700_kfac108-B55","doi-asserted-by":"crossref","first-page":"106577","DOI":"10.1016\/j.vascn.2019.04.003","article-title":"Action potential response of human induced-pluripotent stem cell derived cardiomyocytes to the 28 CiPA compounds: A non-core site data report of the CiPA study","volume":"98","author":"Yu","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/toxsci\/advance-article-pdf\/doi\/10.1093\/toxsci\/kfac108\/47014043\/kfac108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/191\/1\/47\/48949897\/kfac108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/toxsci\/article-pdf\/191\/1\/47\/48949897\/kfac108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:45:59Z","timestamp":1675197959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/191\/1\/47\/6760132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,13]]},"published-print":{"date-parts":[[2023,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfac108","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,10,13]]}}}